AnteoTech Limited Strengthens Life Sciences Momentum with Serum Institute Order and Expanding Global Pipeline
AnteoTech Limited (ASX: ADO) has reported solid progress within its Life Sciences business, highlighted by a US$185,000 (~AU$275,000) order from the Serum Institute of India under its existing five-year supply agreement. The order, alongside expectations of further sales this financial year, reinforces growing customer adoption of AnteoBind. Additional traction includes new sales of approximately AU$70,000 to Japanese customers and a rapidly expanding evaluation pipeline, with 10 new AnteoBind NXT assessments initiated across Europe, North America and Asia since September 2025. The company is also progressing prototype development for ELISA applications and advancing discussions with large global life sciences groups around joint CLIA product development. Comparative studies indicate AnteoBind™ NXT delivers material performance, cost and time advantages versus conventional tosyl chemistry. Collectively, these developments support AnteoTech’s strategy to move up the value chain and position Life Sciences for accelerated growth into 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
AnteoTech Limited Strengthens Life Sciences Momentum with Serum Institute Order and Expanding Global Pipeline
AnteoTech Limited (ASX: ADO) has reported solid progress within its Life Sciences business, highlighted by a US$185,000 (~AU$275,000) order from the Serum Institute of India under its existing five-year supply agreement. The order, alongside expectations of further sales this financial year, reinforces growing customer adoption of AnteoBind. Additional traction includes new sales of approximately AU$70,000 to Japanese customers and a rapidly expanding evaluation pipeline, with 10 new AnteoBind NXT assessments initiated across Europe, North America and Asia since September 2025. The company is also progressing prototype development for ELISA applications and advancing discussions with large global life sciences groups around joint CLIA product development. Comparative studies indicate AnteoBind™ NXT delivers material performance, cost and time advantages versus conventional tosyl chemistry. Collectively, these developments support AnteoTech’s strategy to move up the value chain and position Life Sciences for accelerated growth into 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au